A phase II trial (NCT02609984, Table 2) compared the combination of CMB305 and atezolizumab (anti‐PD‐1) to atezolizumab alone in 89 patients with NY‐ESO‐1‐expressing synovial sarcoma or MLS. This evidence concerns the gene CTAG1B and synovial sarcoma.